TABLE 2.
Treatment, Clinical Outcome and Potential Side Effects
| SARS-CoV-2 Infection-specific Treatment | Yes | (%) | No | (%) | Unknown | (%) | NA | (%) |
|---|---|---|---|---|---|---|---|---|
| Oxygen | 14 | (26%) | 39 | (74%) | 0 | (0%) | 0 | (0%) |
| Dexamethasone | 8 | (15%) | 45 | (85%) | 0 | (0%) | 0 | (0%) |
| Remdesivir | 6 | (11%) | 45 | (85%) | 0 | (0%) | 2 | (4%) |
| Immunomodulatory treatment | 3 | (6%) | 50 | (94%) | 0 | (0%) | 0 | (0%) |
| SARS-CoV-2 mAb product given | ||||||||
| Sotrovimab | 42 | (79%) | 0 | (0%) | 0 | (0%) | 0 | (0%) |
| Casirivimab/Imdevimab | 9 | (17%) | 0 | (0%) | 0 | (0%) | 0 | (0%) |
| Bamlanivimab | 2 | (4%) | 0 | (0%) | 0 | (0%) | 0 | (0%) |
| Reason for SARS-CoV-2 mAb treatment | ||||||||
| Underlying condition | 41 | (77%) | 0 | (0%) | 0 | (0%) | 12 | (23%) |
| Disease severity | 13 | (25%) | 1 | (2%) | 0 | (0%) | 39 | (74%) |
| Clinical outcome | ||||||||
| ICU treatment | 7 | (13%) | 46 | (87%) | 0 | (0%) | 0 | (0%) |
| HFNC | 5 | (9%) | 34 | (64%) | 0 | (0%) | 14 | (26%) |
| Survival | 52 | (98%) | 1 | (2%) | 0 | (0%) | 0 | (0%) |
| Potential side effects reported | ||||||||
| Neutropenia (<0.5 billion/L) | 6 | (11%) | 36 | (68%) | 7 | (13%) | 4 | (8%) |
| Lymphopenia (<0.2 billion/L) | 3 | (6%) | 39 | (74%) | 8 | (15%) | 3 | (6%) |
| ALT rise (>3 times ULN) | 1 | (2%) | 36 | (68%) | 12 | (23%) | 4 | (8%) |
| Thrombosis | 0 | (0%) | 52 | (98%) | 0 | (0%) | 1 | (2%) |
| Chills | 0 | (0%) | 51 | (96%) | 0 | (0%) | 2 | (4%) |
| Nausea or vomiting | 2 | (4%) | 50 | (94%) | 0 | (0%) | 1 | (2%) |
| Bronochospasm | 0 | (0%) | 50 | (94%) | 0 | (0%) | 3 | (6%) |
| Hypotonia | 1 | (2%) | 51 | (96%) | 0 | (0%) | 1 | (2%) |
| Allergic reaction | 0 | (0%) | 51 | (96%) | 0 | (0%) | 2 | (4%) |
| Anaphylaxis | 0 | (0%) | 53 | (100%) | 0 | (0%) | 0 | (0%) |
ALT indicates alanine transaminase; HFNC, high-flow nasal cannula; NA, no information provided by the study center; ULN, upper limit of normal; unknown, information was unknown to the study center.